vs

Side-by-side financial comparison of ACACIA RESEARCH CORP (ACTG) and InfuSystem Holdings, Inc (INFU). Click either name above to swap in a different company.

ACACIA RESEARCH CORP is the larger business by last-quarter revenue ($50.1M vs $36.2M, roughly 1.4× InfuSystem Holdings, Inc). On growth, InfuSystem Holdings, Inc posted the faster year-over-year revenue change (7.0% vs 2.6%). Over the past eight quarters, ACACIA RESEARCH CORP's revenue compounded faster (43.6% CAGR vs 6.4%).

Acacia Research Corporation is a publicly traded American company based in New York City. It acquires and operates businesses in industries including the technology, energy, and industrial/manufacturing sectors. Acacia has a strategic relationship with Starboard Value, LP, the company's controlling shareholder. The company has been characterized as a patent troll.

InfuSystem Holdings, Inc. is a U.S.-headquartered healthcare provider specializing in infusion therapy solutions. It supplies programmable infusion pumps, matching disposable medical consumables, and professional clinical support services, serving oncology clinics, home healthcare providers, and acute care facilities across North America.

ACTG vs INFU — Head-to-Head

Bigger by revenue
ACTG
ACTG
1.4× larger
ACTG
$50.1M
$36.2M
INFU
Growing faster (revenue YoY)
INFU
INFU
+4.4% gap
INFU
7.0%
2.6%
ACTG
Faster 2-yr revenue CAGR
ACTG
ACTG
Annualised
ACTG
43.6%
6.4%
INFU

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACTG
ACTG
INFU
INFU
Revenue
$50.1M
$36.2M
Net Profit
$3.4M
Gross Margin
12.8%
56.4%
Operating Margin
-26.1%
10.3%
Net Margin
6.8%
Revenue YoY
2.6%
7.0%
Net Profit YoY
125.5%
EPS (diluted)
$0.03
$0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACTG
ACTG
INFU
INFU
Q4 25
$50.1M
$36.2M
Q3 25
$59.4M
$36.5M
Q2 25
$51.2M
$36.0M
Q1 25
$124.4M
$34.7M
Q4 24
$48.8M
$33.8M
Q3 24
$23.3M
$35.3M
Q2 24
$25.8M
$33.7M
Q1 24
$24.3M
$32.0M
Net Profit
ACTG
ACTG
INFU
INFU
Q4 25
$3.4M
Q3 25
$-2.7M
$2.3M
Q2 25
$-3.3M
$2.6M
Q1 25
$24.3M
$-267.0K
Q4 24
$-13.4M
Q3 24
$-14.0M
$1.8M
Q2 24
$-8.4M
$717.0K
Q1 24
$-186.0K
$-1.1M
Gross Margin
ACTG
ACTG
INFU
INFU
Q4 25
12.8%
56.4%
Q3 25
21.2%
57.1%
Q2 25
12.8%
55.2%
Q1 25
47.4%
55.2%
Q4 24
17.6%
53.8%
Q3 24
10.1%
53.9%
Q2 24
26.2%
49.5%
Q1 24
49.2%
51.5%
Operating Margin
ACTG
ACTG
INFU
INFU
Q4 25
-26.1%
10.3%
Q3 25
-10.8%
10.4%
Q2 25
-24.2%
10.5%
Q1 25
30.8%
1.8%
Q4 24
-32.4%
7.7%
Q3 24
-44.1%
9.2%
Q2 24
-18.4%
5.5%
Q1 24
-8.6%
-2.6%
Net Margin
ACTG
ACTG
INFU
INFU
Q4 25
6.8%
Q3 25
-4.6%
6.2%
Q2 25
-6.4%
7.2%
Q1 25
19.5%
-0.8%
Q4 24
-27.5%
Q3 24
-60.0%
5.1%
Q2 24
-32.7%
2.1%
Q1 24
-0.8%
-3.5%
EPS (diluted)
ACTG
ACTG
INFU
INFU
Q4 25
$0.03
$0.09
Q3 25
$-0.03
$0.11
Q2 25
$-0.03
$0.12
Q1 25
$0.25
$-0.01
Q4 24
$-0.14
$0.05
Q3 24
$-0.14
$0.08
Q2 24
$-0.08
$0.03
Q1 24
$0.00
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACTG
ACTG
INFU
INFU
Cash + ST InvestmentsLiquidity on hand
$306.7M
$3.2M
Total DebtLower is stronger
$91.9M
$19.6M
Stockholders' EquityBook value
$543.5M
$57.3M
Total Assets
$771.0M
$100.6M
Debt / EquityLower = less leverage
0.17×
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACTG
ACTG
INFU
INFU
Q4 25
$306.7M
$3.2M
Q3 25
$301.8M
$955.0K
Q2 25
$316.7M
$720.0K
Q1 25
$272.0M
$1.5M
Q4 24
$273.9M
$527.0K
Q3 24
$410.9M
$380.0K
Q2 24
$441.9M
$146.0K
Q1 24
$498.4M
$822.0K
Total Debt
ACTG
ACTG
INFU
INFU
Q4 25
$91.9M
$19.6M
Q3 25
$20.9M
Q2 25
$26.3M
Q1 25
$28.7M
Q4 24
$23.9M
Q3 24
$28.0M
Q2 24
$34.2M
Q1 24
$29.9M
Stockholders' Equity
ACTG
ACTG
INFU
INFU
Q4 25
$543.5M
$57.3M
Q3 25
$537.6M
$55.5M
Q2 25
$538.6M
$54.5M
Q1 25
$540.2M
$55.1M
Q4 24
$514.8M
$57.5M
Q3 24
$540.2M
$55.5M
Q2 24
$560.7M
$53.5M
Q1 24
$568.3M
$52.3M
Total Assets
ACTG
ACTG
INFU
INFU
Q4 25
$771.0M
$100.6M
Q3 25
$768.9M
$98.9M
Q2 25
$775.5M
$100.8M
Q1 25
$801.6M
$104.3M
Q4 24
$756.4M
$103.6M
Q3 24
$707.6M
$105.3M
Q2 24
$753.6M
$108.5M
Q1 24
$631.7M
$104.8M
Debt / Equity
ACTG
ACTG
INFU
INFU
Q4 25
0.17×
0.34×
Q3 25
0.38×
Q2 25
0.48×
Q1 25
0.52×
Q4 24
0.41×
Q3 24
0.50×
Q2 24
0.64×
Q1 24
0.57×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACTG
ACTG
INFU
INFU
Operating Cash FlowLast quarter
$75.2M
$7.1M
Free Cash FlowOCF − Capex
$7.0M
FCF MarginFCF / Revenue
19.3%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
22.01×
TTM Free Cash FlowTrailing 4 quarters
$23.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACTG
ACTG
INFU
INFU
Q4 25
$75.2M
$7.1M
Q3 25
$9.5M
$8.5M
Q2 25
$50.1M
$7.0M
Q1 25
$2.4M
$1.8M
Q4 24
$50.1M
$7.9M
Q3 24
$-593.0K
$9.8M
Q2 24
$16.1M
$2.3M
Q1 24
$54.8M
$377.0K
Free Cash Flow
ACTG
ACTG
INFU
INFU
Q4 25
$7.0M
Q3 25
$8.4M
Q2 25
$6.8M
Q1 25
$335.0K
$1.6M
Q4 24
$-98.5M
$7.4M
Q3 24
$-2.8M
$9.8M
Q2 24
$-126.7M
$2.0M
Q1 24
$54.6M
$195.0K
FCF Margin
ACTG
ACTG
INFU
INFU
Q4 25
19.3%
Q3 25
23.1%
Q2 25
18.9%
Q1 25
0.3%
4.7%
Q4 24
-201.8%
21.9%
Q3 24
-12.1%
27.7%
Q2 24
-490.5%
5.9%
Q1 24
224.4%
0.6%
Capex Intensity
ACTG
ACTG
INFU
INFU
Q4 25
0.4%
Q3 25
0.2%
Q2 25
0.6%
Q1 25
1.7%
0.4%
Q4 24
304.4%
1.6%
Q3 24
9.6%
0.1%
Q2 24
553.0%
1.0%
Q1 24
1.1%
0.6%
Cash Conversion
ACTG
ACTG
INFU
INFU
Q4 25
22.01×
Q3 25
3.76×
Q2 25
2.70×
Q1 25
0.10×
Q4 24
Q3 24
5.45×
Q2 24
3.22×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACTG
ACTG

Energy Operations$16.0M32%
Transportation Safety$10.4M21%
Office Storage And Display Solutions$8.4M17%
Printers Consumables And Parts$6.5M13%
Natural Gas Reserves$5.1M10%
Natural Gas Liquids Reserves$3.3M7%

INFU
INFU

Patient Services$20.0M55%
Device Solutions$14.4M40%
Other$1.9M5%

Related Comparisons